RCKT

Rocket Pharmaceuticals, Inc.

RCKT M | $22.82 -2.81% -2.89% 960K

(0.0% 1d) (-15.7% 1m) (26.6% 1y) (0.0% 2d) (-0.8% 3d) (-2.2% 7d) (-13.92% volume)
Earnings Calendar: 2023-08-07
Market Cap: $ 2,065,306,939
http://www.rocketpharma.com
Sec Filling | Patents | 57 employees

(US) Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

cancer gene therapies anemia genetic bone treatment

add to watch list Paper trade email alert is off

Press-releases

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia
Published: 2024-04-02 (Crawled : 11:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| -11.96% | O: -1.76% H: 0.0% C: -1.91%
anemia authorization treatment pharmaceuticals application

Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team
Published: 2024-03-26 (Crawled : 00:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| -12.71% | O: 0.52% H: 0.59% C: -1.78%
pharmaceuticals financial

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| -19.81% | O: 0.07% H: 3.89% C: 1.67%
year pharmaceuticals financial results

Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 00:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| -21.65% | O: -1.47% H: 3.39% C: -0.1%
conference pharmaceuticals

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| -5.25% | O: 0.12% H: 2.9% C: 2.42%
pharmaceuticals

Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
Published: 2023-11-06 (Crawled : 00:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| 11.92% | O: 0.14% H: 1.81% C: -5.14%
pharmaceuticals financial results

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Published: 2023-10-19 (Crawled : 12:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| 39.93% | O: 0.12% H: 2.08% C: 1.55%
congress cell pharmaceuticals therapy

Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Published: 2023-10-02 (Crawled : 15:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| 14.59% | O: 0.29% H: 0.0% C: -5.35%
fda license review treatment pharmaceuticals application

Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock - September 13, 2023
Published: 2023-09-13 (Crawled : 09:00) - biospace.com/
MS | News | $90.66 0.44% 0.07% 8.1M

Finance

| 8.91% | O: 3.47% H: 1.92% C: 1.28%
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| 53.56% | O: 40.22% H: 4.1% C: -0.98%
offering pharmaceuticals

Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
Published: 2023-09-12 (Crawled : 22:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K

Health Technology

| 51.19% | O: 0.64% H: 0.77% C: -2.18%
fda disease rp-a501 pharmaceuticals trial phase 2

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001140361-24-020127	4	2024-04-16	2024-04-15	Sell	M	29624	0
0001140361-24-020127	4	2024-04-16	2024-04-12	Sell	M	70000	29624
0001140361-24-020127	4	2024-04-16	2024-04-15	Sell	S	10000	114784
0001140361-24-020127	4	2024-04-16	2024-04-15	Buy	M	29624	124784
0001140361-24-020127	4	2024-04-16	2024-04-12	Sell	S	10284	95160
0001140361-24-020127	4	2024-04-16	2024-04-12	Sell	S	59716	105444
0001140361-24-020127	4	2024-04-16	2024-04-12	Buy	M	70000	165160
0001140361-24-019167	4	2024-04-11	2024-04-08	Sell	S	12532	75226